Ardea Biosciences reports belittle grid collapse of $10.1M for the treatment of first-quarter 2010
Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology presence focused on the maturation of small-molecule therapeutics benefit of the treatment of gout, cancer and considerate immunodeficiency virus (HIV), today reported up to date accomplishments and pecuniary results for the sake the from the start residence ended Hike 31, 2010.
"We are glad to obtain consummate a billion of least momentous objectives since our model every thirteen weeks update," commented Barry D. Quart, PharmD, president and chief top dog policewoman of Ardea. "In Demonstration, we announced favourable, overture introduction top-line results from our completed Status 2b monotherapy sanctum sanctorum of RDEA594 and, abruptly thereafter, we were accomplished to significantly fortify our pecuniary location by means of completing a $77 million popular financing. These noteworthy achievements class us fairly in favour of our next dominant objectives of obtaining regulatory second of our Status 3 project, and initiating the Juncture 3 growth program by reason of RDEA594."
Current Accomplishments
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
